BioSpace News Archive

Arthur D. Little (ADL) has published The Brave New World Of Synthetic Biology, the latest in a series of leading edge reports from the company’s Blue Shift institute, which explore the impact of new technologies on business, society and people.

PeproMene Bio, Inc. announced that the cohort 1 first patient treated in its Phase 1 relapsed or refractory B-cell acute lymphoblastic leukemia clinical trial of PMB-CT01 has reached complete remission at one-month post treatment.

Simulab Corporation proudly unveils its latest technology - SimuSkin.

Golden Biotechnology Corp. had unveiled the findings of its Phase II clinical trial investigating Antroquinonol in combination with the standard of care: nab-paclitaxel + gemcitabine, as first-line treatment for metastatic pancreatic cancer.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced strategic financing from Blue Owl Capital (Blue Owl) and Canada Pension Plan Investment Board (CPP Investments), through a wholly owned subsidiary (CPPIB Credit) of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion.

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced the publication of a new study1 in The Journal of Clinical and Aesthetic Dermatology (JCAD) which found that using its DecisionDx-SCC test to guide ART decisions for patients with SCC could result in substantial Medicare healthcare savings of up to approximately $972 million annually.

Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug Administration (FDA).

Genflow Biosciences Plc is proud to announce the initiation of two significant research programs backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium.

Genflow Biosciences PLC Announces Two Non-Dilutive Research Grant Awards.

NeuroSigma announced that the U.S. Food and Drug Administration cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder.